Is Bio-Techne Corp (TECH) overvalued? · P/E 65, rev $1.22B
Bio-Techne Corp (TECH) is a biotechnology company listed on US.
This page asks whether Bio-Techne Corp (TECH) looks expensive on cached numbers — not a short thesis.
Latest reported TECH revenue for 2025-06-30 was $1.22B. Net income was $73.4M. Revenue was up 5.2% from 2024-06-30 to 2025-06-30. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
TECH currently screens at market cap $8.49B and trailing P/E 65.2. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next TECH 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the TECH stock page for the full model, not this heading.
Not investment advice.